|
Jun 11
|
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
|
|
May 15
|
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
|
|
May 15
|
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 14
|
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 7
|
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
|
|
Apr 8
|
TRACON Pharmaceuticals Announces Reverse Stock Split
|
|
Apr 3
|
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
|
|
Mar 7
|
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
|
|
Mar 5
|
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
|
|
Dec 20
|
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
|
|
Apr 25
|
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
|